{{Rsnum
|rsid=1256030
|Gene=ESR2
|Chromosome=14
|position=64280452
|Orientation=plus
|GMAF=0.3724
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ESR2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 33.8 | 47.7 | 18.5
| HCB | 43.2 | 50.0 | 6.8
| JPT | 34.1 | 52.3 | 13.6
| YRI | 46.0 | 46.0 | 7.9
| ASW | 0.0 | 0.0 | 0.0
| CHB | 43.2 | 50.0 | 6.8
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID|17889406|OA=1
}}
Among women, [[rs8179176]], [[rs9340799]], [[rs1256065]] and [[rs1256030]] were associated with likelihood of developing cognitive impairment. In men, [[rs728524]], [[rs1255998]], and [[rs1256030]] were associated with cognitive impairment.

{{PharmGKB
|RSID=rs1256030
|Name_s=ESR2:rs1256030
|Gene_s=ESR2
|Feature=
|Evidence=PubMed ID:16949383; PubMed ID:16949384; PubMed ID:16949390; PubMed ID:16949392
|Annotation=Associated with lumbar spine and HDL cholesterol concentration in Chinese premenopausal women.
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161145064
}}

{{PMID Auto
|PMID=16118344
|Title=Polymorphisms in the estrogen receptor beta (ESR2) gene are associated with bone mineral density in Caucasian men and women.
|OA=1
}}

{{PMID Auto
|PMID=18579753
|Title=Vascular actions of estrogens: functional implications.
|OA=1
}}

{{PMID Auto
|PMID=18704709
|Title=Genetic polymorphisms in the estrogen receptor beta (ESR2) gene and the risk of epithelial ovarian carcinoma.
|OA=1
}}

{{PMID Auto
|PMID=19032032
|Title=Associations of the estrogen receptors 1 and 2 gene polymorphisms with the metabolic syndrome in women.
|OA=1
}}

{{PMID Auto
|PMID=19337586
|Title=Do Estrogen Receptor beta Polymorphisms Play A Role in the Pharmacogenetics of Estrogen Signaling?
|OA=1
}}

{{PMID Auto
|PMID=19630952
|Title=Sex steroid metabolism polymorphisms and mammographic density in pre- and early perimenopausal women.
|OA=1
}}

{{PMID Auto
|PMID=20346360
|Title=Genetic risk factors for hepatopulmonary syndrome in patients with advanced liver disease.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs1256030
|overall_frequency_n=83
|overall_frequency_d=128
|overall_frequency=0.648438
|n_genomes=51
|n_genomes_annotated=0
|n_haplomes=73
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}